ChemicalBook--->CAS DataBase List--->835621-08-4

835621-08-4

835621-08-4 Structure

835621-08-4 Structure
IdentificationBack Directory
[Name]

Regorafenib
[CAS]

835621-08-4
[Synonyms]

Regorafenib mesylate
Regorafenib (methanesulfonate)
[Molecular Formula]

C22H19ClF4N4O6S
[MOL File]

835621-08-4.mol
[Molecular Weight]

578.92
Hazard InformationBack Directory
[Uses]

BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
[Definition]

ChEBI:Regorafenib is a pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It is an aromatic ether, a pyridinecarboxamide, a member of monochlorobenzenes, a member of (trifluoromethyl)benzenes, a member of monofluorobenzenes and a member of phenylureas.
[in vivo]

Regorafenib mesylate (10 mg/kg, Orally, single dose or daily for 4 days) inhibits tumor vasculature and tumor growth in a rat GS9L glioblastoma model[1].
Regorafenib mesylate (0-100 mg/kg, Orally, qd × 9) exhibits antitumorigenic and antiangiogenic effects in the Colo-205, MDA-MB-231 and 786-O model[1].

Animal Model:Rat GS9L glioblastoma xenograft[1]
Dosage:10 mg/kg
Administration:Orally, single dose or daily for 4 days
Result:Inhibited tumor vasculature and tumor growth in a rat GS9L glioblastoma model.
Animal Model:Female athymic NCr nu/nu mice, Multiple xenograft models, including models derived from CRC (Colo-205), BC (MDA-MB-231) and RCC (786-O) tumors[1]
Dosage:0, 3, 10, 30, 100 mg/kg
Administration:Orally, qd × 9
Result:Effectively inhibited growth of the Colo-205, MDA-MB-231 and 786-O model. Significantly reduces tumor MVA, effectively inhibited the RAF/MEK/ERK signaling cascade, and drastically inhibited tumor cell proliferation.
[IC 50]

Tie2: 311 ± 46 nM (IC50); Raf-1: 2.5 ± 0.6 nM (IC50); VEGFR2: 4.2 ± 1.6 nM (IC50); VEGFR1: 13 ± 0.4 nM (IC50); BRafV600E: 19 ± 6 nM (IC50); PDGFRβ: 22 ± 3 nM (IC50); B-Raf: 28 ± 10 nM (IC50); VEGFR3: 46 ± 10 nM (IC50)
835621-08-4 suppliers list
Company Name: shandong perfect biotechnology co.ltd
Tel: +86-53169958659 +86-13153181156 , +86-13153181156
Website: http://www.sdperfect.com/about_e/id/1.html
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354 , +17819995354
Website:
Company Name: Jinan Trio PharmaTech Co., Ltd.  
Tel: 0531-88811783
Website: www.trio-pharmatech.com
Company Name: SYN|thesis med chem P/L  
Tel: +86-021-50720296
Website: www.synmedchem.cn
Company Name: Raw material medicin reagent co.,Ltd  
Tel:
Website: http://www.njromanme.com
Company Name: Wuhan FengyaoTonghui Chemical Products Co., Ltd.  
Tel: 027-87466105 15377573527
Website: www.chemicalbook.com/ShowSupplierProductsList30440/0_EN.htm
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Website: https://www.targetmol.cn/
Company Name: Creative Enzymes  
Tel: 1-516-855-7709
Website: www.creative-enzymes.com
Tags:835621-08-4 Related Product Information